Mnemosyne Pharmaceuticals Inc. has closed an additional $6 million in Series A financing for its drug discovery efforts focused on the identification of new drug treatments for schizophrenia and other neuropsychiatric disorders. Edwards Wildman
advised Mnemosyne in this deal, and the team was led by Chris Graham, co-chair of the firm's Business Law Department and co-partner-in-charge of Edwards Wildman's Providence office, and Andrew Capalbo, a Providence-based associate in the firm's Business Law Department. The new financing is from Atlas Venture, a Cambridge, Mass., early stage investment firm dedicated to financing disruptive innovation in life sciences and technology, and from Clal Biotechnology Industries, an Israeli life sciences company, following a milestone funding among the existing Series A investors, including Slater Technology Fund. The new funding brings the total Series A financing raised by Mnemosyne to $11.4 million.